Insulin icodec
Also known as: Awiqli, Icodec, insulin icodec, LY3209590, NN1436, once-weekly insulin, OW insulin icodec
Source Insulin icodec at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Insulin icodec (brand name Icodec) is a long‑acting basal insulin analog engineered for once‑weekly subcutaneous administration, providing stable glycaemic control in type 1 and type 2 diabetes.
Mechanism of Action
Binds and activates the insulin receptor, enhancing peripheral glucose uptake and suppressing hepatic glucose production, with an extended half‑life allowing once‑weekly dosing.
Routes of Administration
Goals & Uses
- Reduced injection frequencyPatient ConvenienceHigh
- Reduction of fasting hyperglycemiaMetabolic / EndocrineHigh
- Glycemic control in type 2 diabetesMetabolicHigh
- Improved treatment adherence through reduced injection frequencyPatient Convenience / AdherenceModerate
- Glycemic control in type 1 diabetesMetabolic / EndocrineHigh
- Glycaemic controlDiabetesHigh
Contraindications
- Hypersensitivity to insulin icodec or any excipientAllergyHigh
- Hypoglycemia (during active episode)MetabolicHigh
- Hypersensitivity to insulin icodec or excipientsAllergy / ImmunologicHigh
- Severe hypoglycaemia unawarenessMetabolicModerate
Adverse Effects
- HypokalemiaElectrolyteUncommon
- HypoglycemiaMetabolicCommonAbnormally low blood glucose
- Allergic reactionsImmunologicalRare
- Injection site reactionsLocalCommon
- Injection‑site reactionsLocalUncommon
- HypoglycaemiaMetabolicCommon
- Weight gainMetabolicCommonIncrease in body weight
- LipodystrophyDermatologicUncommon
Drug Interactions
- Oral antidiabetics (e.g., sulfonylureas, meglitinides)Moderate
- Beta‑blockersModerate
- Beta-blockersModerate
- AlcoholModerate
- GLP-1 receptor agonistsLow
- CorticosteroidsModerate
- SulfonylureasHighMay increase risk of low blood sugar
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patients (<18 years)AgeRelative
- Pediatric (<18 y)AgeRelative
- Type 1 diabetesDisease SpecificRelative
Regulatory Status
- European UnionApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusMarketing authorisation granted in 2024.
- United StatesApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusApproved for once‑weekly subcutaneous injection in adults.
- United KingdomApprovedApproved: Type 1 diabetes mellitus in adults, Type 2 diabetes mellitus in adultsMHRA approval granted following EMA decision; indicated for adults with type 1 and type 2 diabetes.
Approved by FDA (2024) and EMA (2024) for adult patients with type 1 or type 2 diabetes; dosing requires titration based on fasting glucose. Not indicated for pediatric use or pregnancy without specialist supervision.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Insulin icodec?
Insulin icodec (brand name Icodec) is a long‑acting basal insulin analog engineered for once‑weekly subcutaneous administration, providing stable glycaemic control in type 1 and type 2 diabetes.
What is Insulin icodec used for?
Insulin icodec is educationally associated with: Reduced injection frequency, Reduction of fasting hyperglycemia, Glycemic control in type 2 diabetes, Improved treatment adherence through reduced injection frequency, Glycemic control in type 1 diabetes, Glycaemic control. Educational only — not medical advice.
How is Insulin icodec administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Insulin icodec?
Reported adverse effects include: Hypokalemia, Hypoglycemia, Allergic reactions, Injection site reactions, Injection‑site reactions, Hypoglycaemia, Weight gain, Lipodystrophy. This list is not exhaustive — consult a qualified clinician.
Who should avoid Insulin icodec?
Recorded contraindications: Hypersensitivity to insulin icodec or any excipient, Hypoglycemia (during active episode), Hypersensitivity to insulin icodec or excipients, Severe hypoglycaemia unawareness. Consult a qualified clinician before use.